SPOTLIGHT: Altus hires new CEO

Altus Pharmaceuticals has hired Georges Gemayel from Genzyme to be its new CEO. Gemayel had been executive vice president at Genzyme. Both companies are based in Cambridge. Release

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.